Givinostat: First Approval
Drugs · 2024-07 · 84 (7) · 849-856
DOI: 10.1007/s40265-024-02052-1 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drugs, online erschienen am 05.07.2024. Verfasst von Yvette N Lamb. Beteiligte Einrichtung: Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com. Hauptthemen laut MEDLINE: Drug Approval, Carbamates, Muscular Dystrophy, Duchenne, Histone Deacetylase Inhibitors. Die Arbeit wurde bisher 78-mal zitiert (Crossref) und nennt 28 Literaturangaben.
Abstract (Originalsprache)
Givinostat (DUVYZAT™), an orally available histone deacetylase inhibitor, is being developed by Italfarmaco for the treatment of muscular dystrophy and polycythemia vera. Givinostat received its first approval on 21 March 2024, in the USA, for the treatment of Duchenne muscular dystrophy (DMD) in patients 6 years of age and older. Approval was based on the results of the multinational phase III EPIDYS trial, in which givinostat recipients showed less decline than placebo recipients in the time taken to perform a functional task. Givinostat represents the first nonsteroidal treatment for DMD to be approved for use in patients irrespective of the specific genetic variant underlying their disease. Givinostat is available as an oral suspension to be administered twice daily with food. The recommended dosage is based on the body weight of the patient. In the EU, regulatory review of givinostat in DMD is currently underway. This article summarizes the milestones in the development of givinostat leading to this first approval for DMD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.
Zitieren
APA
Lamb, Y. N. (2024). Givinostat: First Approval. Drugs, 84(7), 849-856. https://doi.org/10.1007/s40265-024-02052-1
Vancouver
Lamb YN. Givinostat: First Approval. Drugs. 2024;84(7):849-856. doi:10.1007/s40265-024-02052-1
BibTeX
@article{Lamb2024,
author = {Lamb, Yvette N},
title = {Givinostat: First Approval},
journal = {Drugs},
year = {2024},
volume = {84},
number = {7},
pages = {849--856},
doi = {10.1007/s40265-024-02052-1}
}
EUVIMED